News | September 03, 2014

Willis-Knighton Cancer Center and IBA Complete Acceptance Testing for ProteusONE

Willis-Knighton Cancer Center and IBA Complete Acceptance Testing for ProteusONE

Willis-Knighton Cancer Center

September 3, 2014 — IBA (Ion Beam Applications SA) announced that Willis-Knighton Cancer Center in Shreveport, La., and IBA have completed acceptance testing of the first ProteusONE system ahead of schedule, opening the way to final commissioning and patient treatment with the most advanced compact image-guided IMPT (intensity-modulated proton therapy) solution. The acceptance testing occurred less than 14 months after on-site delivery of the accelerator.

ProteusONE is IBA's single-room proton therapy system that encompasses the latest in targeted proton therapy technologies, including IBA's IMPT and adapT Insight, an advanced image guidance platform for proton therapy. Five units have already been sold by IBA, in Shreveport; Nice, France; Taiwan; and two in Japan.

“We are delighted to have completed the rigorous acceptance testing of ProteusONE at Willis-Knighton Cancer Center ahead of schedule. It is the talent and determination of our teams at IBA and the successful collaboration with Willis-Knighton’s staff that made it possible to achieve this significant milestone. We very much look forward to the first patients being treated at the Willis-Knighton Cancer Center later this year,” said Yves Jongen, founder and chief research officer of IBA.

Added Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Center: “We are very excited to have IMPT become an available option for our patients. Both Willis-Knighton and IBA teams have been partnering at each step to ensure a smooth transition from installation to acceptance testing, leading to a possible first patient treatment in the very near future.”

For more information: www.iba-worldwide.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...